SCHEMBL5282982

SCHEMBL5282982

O=S(=O)(Nc1cccc(F)c1F)c1ccc(Cl)c2nonc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 5/20 0.52
PIK3CA P42336 5/20 0.52
PIK3CB P42338 5/20 0.52
PIK3CG P48736 5/20 0.52
RORA P35398 1/20 0.51
RORC P51449 1/20 0.51
NR1H2 P55055 1/20 0.51
PFKFB3 Q16875 1/20 0.48
POLB P06746 3/20 0.48
KMT2A Q03164 2/20 0.48
GFER P55789 1/20 0.45
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
PTGES2 Q9H7Z7 2/20 0.44
SLC40A1 Q9NP59 3/20 0.44
EGFR P00533 1/20 0.42
RAF1 P04049 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5244817 0.90 RORA (0.53) RORARORCNR1H2PFKFB3POLB
SCHEMBL5293227 0.88 KMT2A (0.54) PIK3CDPIK3CAPIK3CBPIK3CGPOLB
SCHEMBL6395928 0.82 KMT2A (0.70) POLBKMT2AGFERALDH1A1LMNA
SCHEMBL5243229 0.80 ALDH1A1 (0.70) RORARORCNR1H2PFKFB3POLB
SCHEMBL5287473 0.80 ACLY (0.54) PIK3CDRORARORCNR1H2PFKFB3
SCHEMBL8145375 0.80 RORA (0.53) RORARORCNR1H2PFKFB3POLB
SCHEMBL5244185 0.80 RORA (0.50) RORARORCNR1H2PFKFB3POLB
SCHEMBL5243132 0.78 ALDH1A1 (0.51) RORARORCNR1H2PFKFB3POLB
SCHEMBL5278451 0.78 RORA (0.52) RORARORCNR1H2PFKFB3POLB
SCHEMBL5279927 0.78 PFKFB3 (0.62) PIK3CDPIK3CAPIK3CBPIK3CGRORA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP PIK3CD 212/4885PIK3CA 292/4885PIK3CB 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.